Burixafor

Overview

Burixafor (TG-0054) is a potent CXCR4 antagonist with a pIC 50 of 7.4. Burixafor inhibits the binding of CXCL12 to CXCR4 , antagonizes CXCL12 -induced recruitment of Gαᵢ and β-arrestin2, and blocks the downstream Gαᵢ-mediated inhibitory effect on cAMP signal transduction. Burixafor mobilizes CD34 + hematopoietic stem/progenitor cells (HSPC) from the bone marrow to the peripheral blood. Burixafor can be used for research on autologous hematopoietic stem cell transplantation ( ASCT ).

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > CXCR

Product Information

• Catalog No.: HY-19867
• CAS No.: 1191448-17-5
• Molecular Formula: C27H51N8O3P
• Molecular Weight: 566.72
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source